Synergistic effects of vedolizumab and JAK 1,2,3 inhibitors in Crohn’s disease: insights from a systems biology and artificial intelligence-based approach
Our results provide a mechanistic rationale for combining VDZ and JAKi as a potential therapy for CD, advancing the development of more effective and personalised treatment strategies.
Authors
- Silvia Sánchez‐Ramón (ORCID: https://orcid.org/0000-0001-9585-6167)
- Jesús Aparicio (ORCID: https://orcid.org/0000-0002-4736-7999)
- Carmen Montoto-Otero
- Mónica Sierra‐Ausín
- Teresa Letosa-Abián
- Ignacio Marín-Jiménez
Institutions
- Universidad Complutense de Madrid (ES)
- Hospital General Universitario Gregorio Marañón (ES)
- Hospital Clínico San Carlos (ES)
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (ES)
- MeaningCloud (Spain) (ES)
- Complejo Asistencial Universitario de Palencia (ES)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-10
- DOI
- https://doi.org/10.3389/fimmu.2025.1699203
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00